Oh Goody! My disease finally has a famous face! - Page 2 - ZEFRANK.COM

Clytie · 07-04-2005, 12:57 AM

o wow.

*praying*

priceyfatprude · 08-25-2005, 01:32 AM

I emailed Cojo today. I will let you know if I hear anything.

http://et.tv.yahoo.com/celebrities/etsid596230012347/

zenbabe · 08-25-2005, 04:40 AM

What virus was it?

Oh:

POLYOMA VIRUS (BK VIRUS and JC VIRUS) INFECTIONS

The polyoma virus infections are acquired early in childhood, and 60-80% of adults in the U.S. test seropositive for these viruses. The majority of infections are subclinical and lead to viral latency within the kidney. Reactivation occurs in transplant recipients as a result of immunosuppressive therapy. Serologic evidence suggests that the donor kidney may act as the vehicle of transmission. BK or JC virus is shed in the urine of 10-60% of patients after renal transplantation, but clinically significant interstitial nephritis is infrequent.

Clinical presentation

The typical presentation is a rise in the serum creatinine, which cannot be distinguished from rejection or drug toxicity on clinical grounds. A few cases show hydronephrosis on ultrasound examination at the time of allograft biopsy. Intravenous pyelography in these patients may demonstrate a ureteric stricture. Hemorrhagic cystitis is described after bone marrow transplantation.

Pathology Findings

Needle biopsy of the allograft kidney shows a mixed interstitial inflammatory infiltrate with focal tubular injury. The tubular epithelium shows marked anisonucleosis, nuclear atypia, and basophilic or amphophilic intranuclear inclusions. Tubulitis is frequently present, and satisfies the Banff criteria for acute rejection. In addition biopsies may show clusters of neutrophils in the tubular lumen suggestive of pyelonephritis.

Differential diagnosis

Acute tubular injury due to ischaemic or immunologic injury can result in a florid regenerative response with extremely prominent nucleoli, which should not be confused with viral inclusions. Polyoma virus inclusions in biopsy tissue are intranuclear with a homogenous basophilic or amphophilic appearance, which is quite distinct from cytomegalovirus, herpes virus and adenovirus inclusions. Definite identification may be done by immunohistochemistry, in-situ hybridization, or PCR. Electron microscopy is also a useful tool in the differential diagnosis. Polyoma virus particles measure 45-55 nm, while adenovirus measures 70-90nm. Herpes simplex and cytomegalovirus are enveloped virions with a size range of 120-160nm. In formalin fixed tissue viral particles can appear to be smaller than their expected size due to shrinkage artefact.

Treatment

No specific therapy is currently available for polyoma virus infections. Human immune globulins are administered by some clinicians, but their efficacy has not been established. Reduction in immunosuppression is helpful, and results in a decrease in the viral load in follow-up biopsies. Unfortunately, this strategy generally results in graft loss due to rejection. If ureteric stenosis is present, surgical intervention can potentially benefit cases with significant obstruction. However, the clinical response may be limited in cases with concurrent chronic allograft nephropathy.

References

Demeter LM. JC, BK, and other polyomaviruses; progressive multifocal leukoencephalopathy. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Disease. London: Churchill Livingstone, 1995:1400-1406.
Pappo O, Demetris AJ, Raikow RB, et al. Human polyoma virus infection of renal allografts: histopathological diagnosis, clinical significance, and literature review. Mod Pathol 1996;9(2):105-109.
Coleman DV, MacKenzie EF, Gardner SD, et al. Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. J Clin Pathol 1978;31(4):338-347.
Gardner SD, MacKenzie EF, Smith C, et al. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984;37(5):578-586.
Arthur RR, Shah KV, Charache P, et al. BK and JC virus infections in recipients of bone marrow transplants. J Infect Dis 1988;158(3):563-569.
Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus interstitial nephritis in the allograft kidney Transplantation 1999;67:103-109.

zenbabe · 08-25-2005, 04:46 AM

Now shut the fvck up..is this some kind of publicity stunt?

novelty · 08-25-2005, 03:52 PM

Quote:

Originally Posted by priceyfatprude

Like I think he's destined to have a lot of plastic surgery

uh, i think that's already a done deal.

rmr · 08-25-2005, 05:56 PM

i saw him on ET last night and thought of you PFP. he was reading letters/emails from fans -- i'm going to watch again tonight just in case he reads yours

priceyfatprude · 03-07-2006, 02:22 AM

http://www.medicalnewstoday.com/medi...&nfid=rssfeeds

Otsuka Maryland Research Institute, Inc. Granted Fast Track Designation For Tolvaptan In PKD

Main Category: Urology/Nephrology News
Article Date: 25 Feb 2006 - 21:00pm (UK)

Otsuka Maryland Research Institute, Inc. (OMRI) announced that the Food and Drug Administration has granted Fast Track designation to their product tolvaptan for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Fast track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

In citing reasons for granting tolvaptan the Fast Track designation, the agency noted that currently, there is no effective therapy for patients with ADPKD. Tolvaptan is being evaluated as a preventive product for both a serious manifestation of the disease, increased renal size, and the secondary complications such as hypertension, proteinuria and renal pain. The FDA noted that OMRI plans to conduct efficacy studies in patients with ADPKD, and it is believed that tolvaptan might be effective in the treatment of ADPKD based on what is known regarding the pathophysiology of the disease, the known mode of action of tolvaptan, and the results from nonclinical animal model studies. In Phase II studies with PKD subjects, tolvaptan has been associated with side effects that include increased thirst and urination.

OMRI has completed several Phase II clinical trials with tolvaptan in patients with ADPKD, and is beginning global Phase III clinical trials. ADPKD is characterized by the progressive enlargement of focal cysts in both kidneys. Patients with ADPKD suffer from a variety of other morbidities including chronic pain, hypertension, renal hemorrhage and infection. Over 50% of ADPKD patients eventually progress to end-stage renal disease, resulting in dialysis, transplantation, and their associated morbidity and mortality.

For more information about Otsuka's PKD program, please contact 1.866.712.5837.

About Otsuka Maryland Research, Inc. (OMRI)

Otsuka Maryland Research Institute, Inc. is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OMRI is well established in the scientific community as a globally focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The Company is dedicated to the improvement of the quality of human life and health of patients around the world. OMRI is part of the Otsuka Pharmaceutical Group. For additional information, visit http://www.otsuka.com.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with the mission statement: "Otsuka - people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceutical products for the treatment of disease and consumer products for the maintenance of everyday health. The Otsuka Pharmaceutical Group comprises 81 companies and employs approximately 26,000 people in 16 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US $6.2 billion in annual revenues in fiscal 2004.

Otsuka Maryland Research Institute, Inc. http://www.otsuka.com

Avalon · 03-07-2006, 12:17 PM

What is the latest on Coho?

priceyfatprude · 03-08-2006, 02:04 AM

I have no idea. I'm a dumb asshole & posted what I did yesterday in this thread instead of the other one I bumped.

I know he got a kidney (second one!) from his mother. I think he is doing fine, no red carpet though. I think his transplant from Mom was in November. o maybe next season or for the Emmy's???

priceyfatprude · 04-14-2006, 12:38 AM

Teacher to donate kidney to pupil
Source: UPI

NEW LENOX, Ill. (UPI) -- An Illinois teacher is giving an unusual gift to a sick student -- one of her kidneys.

Patricia Donahue, 26, a fourth-grade teacher at the Oster-Oakview School in New Lenox decided to get tested to see if she would be a match for 10-year-old Brandon Shafer when she learned that his mother would not be able to donate, the Joliet (Ill.) Herald-News reported. Brandon told her when she asked him about the problem when she asked him why he looked sad.

Brandon suffers from polycystic kidney disease. The disease, which was diagnosed when he was 8, has stunted his growth. If Donahue had not come forward, he would have had to wait for more than a year for a transplant, the newspaper said.

Donahue, a former Peace Corps volunteer, told the Herald-News she was inspired by her own father's bout with leukemia several years ago when his life was saved by donated bone marrow. She sees a higher power at work as well.

"There's a reason why he was placed in my class," Donahue said.

The surgery is scheduled May 10.

priceyfatprude · 06-22-2006, 01:12 AM

I'm posting my kidney news in here. If you don't like it, you may kindly find another of the 300,000 posts here @ zefark.com & read it instead.

http://www.pkdcure.org/site/PageServ..._morerapamycin

This drug^^ is NOT the one I am currently testing for the FDA, it's a different one. Basically if this one does not work, we have a backup in place.

More & more research & you know what? You have all helped with that, by sponsoring me in our Walk for PKD these last 2 years.

I so appreciate that.

Jack Flanders · 06-22-2006, 01:33 AM

When is the walk? I would be interested in sponsoring you. A very old friend of mine donated a kidney to her brother 30 years ago which helped him for almost 25 years. Fortunately, his uncle was a match for a new transplant and all seems to be going well.

priceyfatprude · 06-23-2006, 12:14 AM

September 17 is our walk. I will put up a link once I make the page.

07-04-2005, 12:57 AM	#16
Clytie thundering is my favorite Join Date: Apr 2004 Location: motivated to be all i can be Posts: 3,827	o wow. praying __________________ your star shaped heart has reached out to me and together our hearts beat as one bound by the rich red that runs coarsing united we stand stronger than before able to face the dark with hands entwined

08-25-2005, 01:32 AM	#17
priceyfatprude girthy pickles Join Date: Feb 2003 Location: under your desk Posts: 9,313	I emailed Cojo today. I will let you know if I hear anything. http://et.tv.yahoo.com/celebrities/etsid596230012347/ __________________ "We like your board's features...but don't care about it's people"

08-25-2005, 04:40 AM	#18
zenbabe Lollypop! Join Date: Sep 2002 Location: we are all made of stars Posts: 11,690	What virus was it? Oh: POLYOMA VIRUS (BK VIRUS and JC VIRUS) INFECTIONS The polyoma virus infections are acquired early in childhood, and 60-80% of adults in the U.S. test seropositive for these viruses. The majority of infections are subclinical and lead to viral latency within the kidney. Reactivation occurs in transplant recipients as a result of immunosuppressive therapy. Serologic evidence suggests that the donor kidney may act as the vehicle of transmission. BK or JC virus is shed in the urine of 10-60% of patients after renal transplantation, but clinically significant interstitial nephritis is infrequent. Clinical presentation The typical presentation is a rise in the serum creatinine, which cannot be distinguished from rejection or drug toxicity on clinical grounds. A few cases show hydronephrosis on ultrasound examination at the time of allograft biopsy. Intravenous pyelography in these patients may demonstrate a ureteric stricture. Hemorrhagic cystitis is described after bone marrow transplantation. Pathology Findings Needle biopsy of the allograft kidney shows a mixed interstitial inflammatory infiltrate with focal tubular injury. The tubular epithelium shows marked anisonucleosis, nuclear atypia, and basophilic or amphophilic intranuclear inclusions. Tubulitis is frequently present, and satisfies the Banff criteria for acute rejection. In addition biopsies may show clusters of neutrophils in the tubular lumen suggestive of pyelonephritis. Differential diagnosis Acute tubular injury due to ischaemic or immunologic injury can result in a florid regenerative response with extremely prominent nucleoli, which should not be confused with viral inclusions. Polyoma virus inclusions in biopsy tissue are intranuclear with a homogenous basophilic or amphophilic appearance, which is quite distinct from cytomegalovirus, herpes virus and adenovirus inclusions. Definite identification may be done by immunohistochemistry, in-situ hybridization, or PCR. Electron microscopy is also a useful tool in the differential diagnosis. Polyoma virus particles measure 45-55 nm, while adenovirus measures 70-90nm. Herpes simplex and cytomegalovirus are enveloped virions with a size range of 120-160nm. In formalin fixed tissue viral particles can appear to be smaller than their expected size due to shrinkage artefact. Treatment No specific therapy is currently available for polyoma virus infections. Human immune globulins are administered by some clinicians, but their efficacy has not been established. Reduction in immunosuppression is helpful, and results in a decrease in the viral load in follow-up biopsies. Unfortunately, this strategy generally results in graft loss due to rejection. If ureteric stenosis is present, surgical intervention can potentially benefit cases with significant obstruction. However, the clinical response may be limited in cases with concurrent chronic allograft nephropathy. References Demeter LM. JC, BK, and other polyomaviruses; progressive multifocal leukoencephalopathy. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Disease. London: Churchill Livingstone, 1995:1400-1406. Pappo O, Demetris AJ, Raikow RB, et al. Human polyoma virus infection of renal allografts: histopathological diagnosis, clinical significance, and literature review. Mod Pathol 1996;9(2):105-109. Coleman DV, MacKenzie EF, Gardner SD, et al. Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. J Clin Pathol 1978;31(4):338-347. Gardner SD, MacKenzie EF, Smith C, et al. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984;37(5):578-586. Arthur RR, Shah KV, Charache P, et al. BK and JC virus infections in recipients of bone marrow transplants. J Infect Dis 1988;158(3):563-569. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus interstitial nephritis in the allograft kidney Transplantation 1999;67:103-109. __________________ Be yourself, because the people that mind don't matter, and the people that matter don't mind. -Dr. Seuss Last edited by zenbabe : 08-25-2005 at 04:44 AM.

08-25-2005, 04:46 AM	#19
zenbabe Lollypop! Join Date: Sep 2002 Location: we are all made of stars Posts: 11,690	Now shut the fvck up..is this some kind of publicity stunt? __________________ Be yourself, because the people that mind don't matter, and the people that matter don't mind. -Dr. Seuss

03-07-2006, 02:22 AM	#22
priceyfatprude girthy pickles Join Date: Feb 2003 Location: under your desk Posts: 9,313	http://www.medicalnewstoday.com/medi...&nfid=rssfeeds Otsuka Maryland Research Institute, Inc. Granted Fast Track Designation For Tolvaptan In PKD Main Category: Urology/Nephrology News Article Date: 25 Feb 2006 - 21:00pm (UK) Otsuka Maryland Research Institute, Inc. (OMRI) announced that the Food and Drug Administration has granted Fast Track designation to their product tolvaptan for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Fast track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. In citing reasons for granting tolvaptan the Fast Track designation, the agency noted that currently, there is no effective therapy for patients with ADPKD. Tolvaptan is being evaluated as a preventive product for both a serious manifestation of the disease, increased renal size, and the secondary complications such as hypertension, proteinuria and renal pain. The FDA noted that OMRI plans to conduct efficacy studies in patients with ADPKD, and it is believed that tolvaptan might be effective in the treatment of ADPKD based on what is known regarding the pathophysiology of the disease, the known mode of action of tolvaptan, and the results from nonclinical animal model studies. In Phase II studies with PKD subjects, tolvaptan has been associated with side effects that include increased thirst and urination. OMRI has completed several Phase II clinical trials with tolvaptan in patients with ADPKD, and is beginning global Phase III clinical trials. ADPKD is characterized by the progressive enlargement of focal cysts in both kidneys. Patients with ADPKD suffer from a variety of other morbidities including chronic pain, hypertension, renal hemorrhage and infection. Over 50% of ADPKD patients eventually progress to end-stage renal disease, resulting in dialysis, transplantation, and their associated morbidity and mortality. For more information about Otsuka's PKD program, please contact 1.866.712.5837. About Otsuka Maryland Research, Inc. (OMRI) Otsuka Maryland Research Institute, Inc. is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OMRI is well established in the scientific community as a globally focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The Company is dedicated to the improvement of the quality of human life and health of patients around the world. OMRI is part of the Otsuka Pharmaceutical Group. For additional information, visit http://www.otsuka.com. Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with the mission statement: "Otsuka - people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceutical products for the treatment of disease and consumer products for the maintenance of everyday health. The Otsuka Pharmaceutical Group comprises 81 companies and employs approximately 26,000 people in 16 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US $6.2 billion in annual revenues in fiscal 2004. Otsuka Maryland Research Institute, Inc. http://www.otsuka.com __________________ "We like your board's features...but don't care about it's people"

08-25-2005, 05:56 PM	#21
rmr Moderator Join Date: Sep 2002 Posts: 10,595	i saw him on ET last night and thought of you PFP. he was reading letters/emails from fans -- i'm going to watch again tonight just in case he reads yours

03-07-2006, 12:17 PM	#23
Avalon Moderator Join Date: Feb 2004 Location: A much better place Posts: 5,931	What is the latest on Coho? __________________ I, not events, have the power to make me happy or unhappy today. I can choose which it shall be. Yesterday is dead, tomorrow hasn't arrived yet. I have just one day, today, and I'm going to be happy in it. Groucho Marx

03-08-2006, 02:04 AM	#24
priceyfatprude girthy pickles Join Date: Feb 2003 Location: under your desk Posts: 9,313	I have no idea. I'm a dumb asshole & posted what I did yesterday in this thread instead of the other one I bumped. I know he got a kidney (second one!) from his mother. I think he is doing fine, no red carpet though. I think his transplant from Mom was in November. o maybe next season or for the Emmy's??? __________________ "We like your board's features...but don't care about it's people"

04-14-2006, 12:38 AM	#25
priceyfatprude girthy pickles Join Date: Feb 2003 Location: under your desk Posts: 9,313	Teacher to donate kidney to pupil Source: UPI NEW LENOX, Ill. (UPI) -- An Illinois teacher is giving an unusual gift to a sick student -- one of her kidneys. Patricia Donahue, 26, a fourth-grade teacher at the Oster-Oakview School in New Lenox decided to get tested to see if she would be a match for 10-year-old Brandon Shafer when she learned that his mother would not be able to donate, the Joliet (Ill.) Herald-News reported. Brandon told her when she asked him about the problem when she asked him why he looked sad. Brandon suffers from polycystic kidney disease. The disease, which was diagnosed when he was 8, has stunted his growth. If Donahue had not come forward, he would have had to wait for more than a year for a transplant, the newspaper said. Donahue, a former Peace Corps volunteer, told the Herald-News she was inspired by her own father's bout with leukemia several years ago when his life was saved by donated bone marrow. She sees a higher power at work as well. "There's a reason why he was placed in my class," Donahue said. The surgery is scheduled May 10. __________________ "We like your board's features...but don't care about it's people"

06-22-2006, 01:12 AM	#26
priceyfatprude girthy pickles Join Date: Feb 2003 Location: under your desk Posts: 9,313	I'm posting my kidney news in here. If you don't like it, you may kindly find another of the 300,000 posts here @ zefark.com & read it instead. http://www.pkdcure.org/site/PageServ..._morerapamycin This drug^^ is NOT the one I am currently testing for the FDA, it's a different one. Basically if this one does not work, we have a backup in place. More & more research & you know what? You have all helped with that, by sponsoring me in our Walk for PKD these last 2 years. I so appreciate that. __________________ "We like your board's features...but don't care about it's people" Last edited by priceyfatprude : 06-22-2006 at 11:56 PM.

06-22-2006, 01:33 AM	#27
Jack Flanders landscaping is fun Join Date: Aug 2005 Location: up river and down river Posts: 4,815	When is the walk? I would be interested in sponsoring you. A very old friend of mine donated a kidney to her brother 30 years ago which helped him for almost 25 years. Fortunately, his uncle was a match for a new transplant and all seems to be going well.

06-23-2006, 12:14 AM	#28
priceyfatprude girthy pickles Join Date: Feb 2003 Location: under your desk Posts: 9,313	September 17 is our walk. I will put up a link once I make the page. __________________ "We like your board's features...but don't care about it's people"

Thread Tools
Show Printable Version Email this Page
Display Modes	Rate This Thread
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode	Rate This Thread: